Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Acurx Pharmaceuticals. The associated price target is $30.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors including Acurx Pharmaceuticals’ promising developments with ibezapolstat, a new class of antibiotic targeting C. difficile infection. The drug has shown a low risk of disrupting the gut microbiome compared to other antibiotics, which is a significant advantage. Additionally, recent data presented at the IDWeek 2025 Scientific Conference and published in ‘Nature Communications’ highlight the drug’s unique mechanism of action and potential benefits.
Furthermore, Acurx has made significant progress in its clinical trials, with a high clinical cure rate observed in Phase 2b studies. The company has also received positive regulatory feedback from both the FDA and EU regulators, paving the way for Phase 3 trials. These developments, combined with the strategic importance of developing new antimicrobials domestically, contribute to McCarthy’s optimistic outlook on the company’s future prospects.
According to TipRanks, McCarthy is an analyst with an average return of -14.4% and a 33.20% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SCYNEXIS, Neuphoria Therapeutics, and OS Therapies Incorporated.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $31.00 price target.